Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial (Q44529446)

3 December 2017

title

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial (English)

1 reference

multicenter clinical trial

3 December 2017

main subject

1 reference

1 reference

acute myeloid leukemia

1 reference

R F Schlenk

1

1 reference

3 December 2017

A Benner

2

1 reference

3 December 2017

F Hartmann

3

1 reference

3 December 2017

F del Valle

4

1 reference

3 December 2017

C Weber

5

1 reference

3 December 2017

H Pralle

6

1 reference

3 December 2017

J Th Fischer

7

1 reference

3 December 2017

U Gunzer

8

1 reference

3 December 2017

A Pezzutto

9

1 reference

3 December 2017

W Weber

10

1 reference

3 December 2017

W Grimminger

11

1 reference

3 December 2017

J Preiss

12

1 reference

3 December 2017

M Hensel

13

1 reference

3 December 2017

S Fröhling

14

1 reference

3 December 2017

K Döhner

15

1 reference

3 December 2017

R Haas

16

1 reference

3 December 2017

H Döhner

17

1 reference

3 December 2017

AML Study Group Ulm (AMLSG ULM)

18

1 reference

3 December 2017

publication date

1 August 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

17

1 reference

3 December 2017

issue

8

1 reference

3 December 2017

page(s)

1521-1528

1 reference

The clinical significance of karyotype in acute myelogenous leukemia.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Clinical importance of cytogenetics in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Censoring distributions as a measure of follow-up in survival analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403009

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403009

1 reference

3 December 2017

1 reference